Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality
IntroductionNeuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses. As regards COVID-19 patients (COVID+) requiring oxygen supply, to date nobody has studied CST as a potential mediator in the regulation of immunity.Patients & MethodsAdmission pl...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.985472/full |
| _version_ | 1797980883719815168 |
|---|---|
| author | Francis Schneider Francis Schneider Pierrick Le Borgne Jean-Etienne Herbrecht François Danion Morgane Solis Sophie Hellé Cosette Betscha Raphaël Clere-Jehl François Lefebvre Vincent Castelain Yannick Goumon Marie-Hélène Metz-Boutigue |
| author_facet | Francis Schneider Francis Schneider Pierrick Le Borgne Jean-Etienne Herbrecht François Danion Morgane Solis Sophie Hellé Cosette Betscha Raphaël Clere-Jehl François Lefebvre Vincent Castelain Yannick Goumon Marie-Hélène Metz-Boutigue |
| author_sort | Francis Schneider |
| collection | DOAJ |
| description | IntroductionNeuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses. As regards COVID-19 patients (COVID+) requiring oxygen supply, to date nobody has studied CST as a potential mediator in the regulation of immunity.Patients & MethodsAdmission plasma CST and CgA - its precursor - concentrations were measured (ELISA test) in 73 COVID+ and 27 controls. Relationships with demographics, comorbidities, disease severity and outcomes were analysed (Mann-Whitney, Spearman correlation tests, ROC curves).ResultsAmong COVID+, 49 required ICU-admission (COVID+ICU+) and 24 standard hospitalization (COVID+ICU-). Controls were either healthy staff (COVID-ICU-, n=11) or (COVID-ICU+, patients n=16). Median plasma CST were higher in COVID+ than in controls (1.6 [1.02; 3.79] vs 0.87 [0.59; 2.21] ng/mL, p<0.03), with no difference between COVID+ and COVID-ICU+. There was no difference between groups in either CgA or CST/CgA ratios, but these parameters were lower in healthy controls (p<0.01). CST did not correlate with either hypoxia- or usual inflammation-related parameters. In-hospital mortality was similar whether COVID+ or not, but COVID+ had longer oxygen support and more complications (p<0.03). CST concentrations and the CST/CgA ratio were associated with in-hospital mortality (p<0.01) in COVID+, whereas CgA was not. CgA correlated with care-related infections (p<0.001).ConclusionRespiratory COVID patients release significant amounts of CST in the plasma making this protein widely available for the neural regulation of immunity. If confirmed prospectively, plasma CST will reliably help in predicting in-hospital mortality, whereas CgA will facilitate the detection of patients prone to care-related infections. |
| first_indexed | 2024-04-11T06:00:51Z |
| format | Article |
| id | doaj.art-4e519e549b614e9cb6c1438552678dc0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T06:00:51Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-4e519e549b614e9cb6c1438552678dc02022-12-22T04:41:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.985472985472Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortalityFrancis Schneider0Francis Schneider1Pierrick Le Borgne2Jean-Etienne Herbrecht3François Danion4Morgane Solis5Sophie Hellé6Cosette Betscha7Raphaël Clere-Jehl8François Lefebvre9Vincent Castelain10Yannick Goumon11Marie-Hélène Metz-Boutigue12Médecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceInstitut National de la Santé et de la Recherche Médicale-Unité Mixte de Recherche (INSERM-UMR) 1121 Biomatériaux et Bio-ingénierie, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceService d’accueil des urgences, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceMédecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceMaladies Infectieuses et Tropicales, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceLaboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Faculté de Médecine and Unistra, Strasbourg, FranceInstitut National de la Santé et de la Recherche Médicale-Unité Mixte de Recherche (INSERM-UMR) 1121 Biomatériaux et Bio-ingénierie, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceInstitut National de la Santé et de la Recherche Médicale-Unité Mixte de Recherche (INSERM-UMR) 1121 Biomatériaux et Bio-ingénierie, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceMédecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FrancePôle de Santé Publique, Groupe de Méthodes en Recheche Clinique (GRMC), Hôpitaux Universitaires de Strasbourg, Unistra, Strasbourg, FranceMédecine Intensive Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceCentre National de la Recherche Scientifique-Unité Propre de Recherche (CNRS-UPR) 3212, Institut des Neurosciences Cellulaires et Intégratives, Unistra, Strasbourg, FranceInstitut National de la Santé et de la Recherche Médicale-Unité Mixte de Recherche (INSERM-UMR) 1121 Biomatériaux et Bio-ingénierie, Fédération de Médecine Translationnelle de Strasbourg (FMTS) and Unistra, Strasbourg, FranceIntroductionNeuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses. As regards COVID-19 patients (COVID+) requiring oxygen supply, to date nobody has studied CST as a potential mediator in the regulation of immunity.Patients & MethodsAdmission plasma CST and CgA - its precursor - concentrations were measured (ELISA test) in 73 COVID+ and 27 controls. Relationships with demographics, comorbidities, disease severity and outcomes were analysed (Mann-Whitney, Spearman correlation tests, ROC curves).ResultsAmong COVID+, 49 required ICU-admission (COVID+ICU+) and 24 standard hospitalization (COVID+ICU-). Controls were either healthy staff (COVID-ICU-, n=11) or (COVID-ICU+, patients n=16). Median plasma CST were higher in COVID+ than in controls (1.6 [1.02; 3.79] vs 0.87 [0.59; 2.21] ng/mL, p<0.03), with no difference between COVID+ and COVID-ICU+. There was no difference between groups in either CgA or CST/CgA ratios, but these parameters were lower in healthy controls (p<0.01). CST did not correlate with either hypoxia- or usual inflammation-related parameters. In-hospital mortality was similar whether COVID+ or not, but COVID+ had longer oxygen support and more complications (p<0.03). CST concentrations and the CST/CgA ratio were associated with in-hospital mortality (p<0.01) in COVID+, whereas CgA was not. CgA correlated with care-related infections (p<0.001).ConclusionRespiratory COVID patients release significant amounts of CST in the plasma making this protein widely available for the neural regulation of immunity. If confirmed prospectively, plasma CST will reliably help in predicting in-hospital mortality, whereas CgA will facilitate the detection of patients prone to care-related infections.https://www.frontiersin.org/articles/10.3389/fimmu.2022.985472/fullInnate immunityCOVIDCatestatinChromogranin Ahypoxiacritically ill |
| spellingShingle | Francis Schneider Francis Schneider Pierrick Le Borgne Jean-Etienne Herbrecht François Danion Morgane Solis Sophie Hellé Cosette Betscha Raphaël Clere-Jehl François Lefebvre Vincent Castelain Yannick Goumon Marie-Hélène Metz-Boutigue Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality Frontiers in Immunology Innate immunity COVID Catestatin Chromogranin A hypoxia critically ill |
| title | Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality |
| title_full | Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality |
| title_fullStr | Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality |
| title_full_unstemmed | Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality |
| title_short | Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality |
| title_sort | assessment of plasma catestatin in covid 19 reveals a hitherto unknown inflammatory activity with impact on morbidity mortality |
| topic | Innate immunity COVID Catestatin Chromogranin A hypoxia critically ill |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.985472/full |
| work_keys_str_mv | AT francisschneider assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT francisschneider assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT pierrickleborgne assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT jeanetienneherbrecht assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT francoisdanion assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT morganesolis assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT sophiehelle assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT cosettebetscha assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT raphaelclerejehl assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT francoislefebvre assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT vincentcastelain assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT yannickgoumon assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality AT mariehelenemetzboutigue assessmentofplasmacatestatinincovid19revealsahithertounknowninflammatoryactivitywithimpactonmorbiditymortality |